Kane Biotech Announces Publication of revyve(TM) Wound Gel Article in the International Wound Journal

Executive Summary

• Kane Biotech announced that its revyve® Antimicrobial Wound Gel was featured in a peer‑reviewed article in the International Wound Journal.
• The study demonstrated rapid (30 min) 99.99%–99.9999% bacterial kill rates against key wound pathogens and sustained activity for up to 7 days, supporting the gel’s clinical potential.
• Interim CEO Dr. Robert Huizinga highlighted the publication as independent validation that strengthens credibility with clinicians, regulators and commercial partners.

Key Details

• Article title: “Wound Healing Property of a Novel Thermo‑Reversible Wound Gel With Lasting Antimicrobial and Antibiofilm Activity.”
• First author: Dr. Jeyachchandran Visvalingam (Internal R&D Leader, Kane Biotech). Co‑authors include researchers from the Miller School of Medicine, University of Miami.
• Key scientific findings:
• Thermo‑reversible gel transitions from low‑viscosity liquid to body‑temperature gel and re‑liquefies when cooled for atraumatic removal.
• Achieved 99.99%–99.9999% reduction in bacterial counts of Staphylococcus aureus and Pseudomonas aeruginosa within 30 minutes.
• In‑vitro antimicrobial activity persisted for up to 7 days, potentially reducing dressing changes.
• Safety confirmed via biocompatibility testing and a porcine wound‑healing study (non‑cytotoxic).
• Regulatory status reiterated: revyve® Antimicrobial Wound Gel is U.S. FDA 510(k) cleared and Health Canada approved (as are the spray and cleanser variants).
• Quote from Interim CEO Dr. Robert Huizinga: “Having our research published in the International Wound Journal underscores the scientific rigor behind revyve technology… strengthens our credibility with clinicians, regulators and commercial partners.”

Notable Quotes

“Recognition in such a respected global wound‑care publication strengthens our credibility with clinicians, regulators and commercial partners, and reinforces our commitment to advancing evidence‑based solutions that improve patient outcomes.” – Dr. Robert Huizinga, Interim CEO

Materiality Assessment: Non‑Material – Positive (the release provides positive scientific validation but does not disclose new financial or operational metrics).